• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    G

    Genesis Medical Center

    46论文总数
    308引用总数

    Genesis Health System is a not-for-profit healthcare system based in Davenport, Iowa. Genesis Health System provides health services to multiple communities in Eastern Iowa and Western Illinois. Genesis Health System operates and manages 6 different hospitals. Genesis is the largest employer in Scott County, Iowa and the third largest in the Quad City area with 5,200 employees. The President and CEO of Genesis Health System is Doug Cropper..

    论文量&引用量时间轴

    机构学者

    论文(45)

    年份
    起
    –
    止
    排序
    1NAPOLI 3, a Phase 3 Study of NALIRIFOX in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mpdac): Final Overall Survival (OS) Analysis and Characteristics of the Long-Term Survivors.
    Vincent Chung, Mark D. Kochenderfer, Nagendra Natarajan,Grant Richard Williams, Ashley Ann Laursen,Paul Cockrum, Whitney Rhodes,Andy Surinach, Li Zhang,Jia Li,Fiona Maxwell,Eileen M. O'Reilly,

    LBA4175 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall survival (mOS) of between 8 and 11 months. With the use of modern chemotherapy regimens, some patients with mPDAC have been shown to achieve long‐term survival of 18 months or longer (Rochefort et al. Oncol. 2019;24:1543–8). The aim of this analysis was to describe long‐term survivors among the North American population treated with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in the NAPOLI 3 trial and to explore clinical and pathological factors that might be associated with prolonged survival. Methods: Patients with confirmed untreated mPDAC randomized to receive NALIRIFOX in NAPOLI 3 were treatment on days 1 and 15 of a 28-day cycle. In this post hoc analysis of patients enrolled from centers in North America (n = 120), baseline characteristics and NALIRIFOX dosing patterns were evaluated for individuals who survived for 18 months of longer (long-term survivors; n = 15). The analysis was descriptive; no statistical tests were performed. Kaplan–Meier methods were used to estimate mOS (interquartile range [IQR]). Results: Among the long-term survivors, the mOS was 19.5 (IQR: 18.8–22.6) months and 53.3% were male. At baseline, long-term survivors had a median age of 61.0 (IQR: 49.0–70.5) years, had a median CA 19-9 level of 166.8 U/ml (IQR: 32.7–1728.4), 53.3% had Eastern Cooperative Oncology Group Performance Score (ECOG PS) 0, 53.3% had the main pancreatic tumor located in the body of the pancreas, 66.7% had liver metastasis, and 53.3% had ≥ 3 metastatic sites. Liposomal irinotecan and oxaliplatin dose reductions were experienced by 66.7% and 80.0% of long-term survivors, respectively, and dose delays by 86.7% and 80.0%, respectively. Median cumulative dose of liposomal irinotecan was 1229.4 (IQR: 821.9–1513.9) mg/m 2 for long-term survivors and median cumulative dose of oxaliplatin was 962.3 (655.0–1470.3) mg/ml. Median duration of exposure was 65.1 (IQR: 40.1–89.0) weeks for liposomal irinotecan and 39.9 (26.6–76.4) weeks for oxaliplatin. Conclusions: This post hoc analysis investigated characteristics and dosing patterns of long-term survivors from NAPOLI 3 treated with NALIRIFOX in North America. Patients with prolonged OS were generally younger (vs typical mPDAC diagnosis), few had tumors in the head or tail of the pancreas and, overall, CA19-9 levels and ECOG PS were low. A large proportion of long-term survivors experienced liposomal irinotecan and/or oxaliplatin dose reductions or treatment delays, but had prolonged exposure and high cumulative doses of both drugs. Despite liver metastasis and ≥ 3 metastatic sites in a substantial proportion of long-term survivors, dose modifications and an otherwise good clinical profile enabled attainment of a long mOS. Small sample size limits the generalizability of these results. Clinical trial information: NCT04083235 .

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)引用:1
    引用
    AI阅读
    加入学术空间
    2Analisis Jalur: Efektivitas Program Kesehatan Responsif Gender “aksi Bergizi” Terhadap Perilaku Remaja Sadar Gizi Dengan Pendekatan Theory of Planned Behavior Di Kota Depok
    Valentina Dili,Hayatun Nufus, Triya Amalina

    Kebiasaan makan dan perilaku hidup sehat pada remaja putri perlu mendapatkan perhatian untuk mencegah permasalahan gizi yang berkepanjangan dan bebas stunting. Perubahan perilaku ini memerlukan kerja sama dari berbagai pihak melalui strategi komunikasi perubahan sosial dan perilaku. Tujuan penelitian ini adalah menganalisis efektivitas program aksi bergizi terhadap perilaku sadar gizi dengan pendekatan theory of planned behavior. Metode yang digunakan dalam penelitian ini adalah kombinasi survey analitik dan posttest only control group design. Penelitian dilaksanakan pada bulan Oktober 2024 di SMP 6 Depok dan SMK 1 Depok. Sampel yang digunakan dalam penelitian ini sebanyak 108 remaja putri. Teknik sampling yang digunakan adalah purposive sampling. Data hasil penelitian dianalisis menggunakan analisis jalur dengan bantuan STATA 17. Hasil penelitian menunjukkan bahwa aksi bergizi, penyuluhan teman sebaya, dan media kipas edukasi berhubungan secara tidak langsung dengan perilaku melalui variabel antara niat. Aksi bergizi memiliki pengaruh terhadap niat remaja sadar gizi (b = 1,14; p = 0,032). Penyuluhan teman sebaya dari luar sekolah memiliki pengaruh terhadap niat remaja sadar gizi (b = 2,51; p < 0,001). Media edukasi memiliki pengaruh terhadap niat remaja sadar gizi (b = 1,90; p < 0,001). Niat berhubungan langsung dengan perilaku remaja sadar gizi (b = 2,54; CI 95% = 1,61 hingga 3,48; p < 0,001). Temuan penelitian ini menunjukkan bahwa theory of planned behavior tepat digunakan untuk menganalisis efektivitas program aksi bergizi.

    2025Indonesian Journal on Medical Science(2025)
    引用
    AI阅读
    加入学术空间
    3DEVELOPMENT AND CHARACTERIZATION OF INNOVATIVE BAR SOAP FORMULATIONS USING GAYO ARABICA COFFEE HUSK EXTRACT: FOCUSING ON PHYSICAL PROPERTIES AND ANTIBACTERIAL ACTIVITY USING PH METER SENSOR
    Siwi Putri Andini, Rori Theresia, Lawrence Adi Supriyono

    This study aims to examine the characteristics of solid soap made from Gayo Arabica coffee shell extract from Aceh, a premium commodity rich in active compounds. Coffee, which has become part of modern lifestyle, is now used not only as a beverage but also in cosmetic and pharmaceutical products. In this research, solid soap was formulated with varying concentrations of coffee extract at 1%, 2%, and 4%, with 2% triclosan used as a positive control. Physical and microbiological characteristics were tested according to SNI 3532:2021 standards, including tests for pH, moisture content, free alkali content, foam stability, and antibacterial activity against Staphylococcus aureus. Test results showed that all soap formulations met SNI standards, with pH ranging from 9.59 to 10.10, moisture content between 5.60% and 9.36%, safe free alkali content for the skin, foam height between 5-5.8 cm, and antibacterial inhibition zones against Staphylococcus aureus ranging from 7.4 to 9.2 cm. In conclusion, solid soap with Gayo Aceh coffee shell extract meets SNI quality standards and has promising antibacterial potential.

    2025Jurnal Ilmu dan Teknologi Kesehatan(2025)
    引用
    AI阅读
    加入学术空间
    4Evaluating Future IVD Plasma P-Tau 181 and ApoE4 Immunoassays for Rule out of Amyloid Pathology in a Multi-Center Study Reflective of Routine Clinical Practice (P7-3.017)
    Imke Kirste, Sayuri Hortsch, Sheila Baez-Torres, Merce Boada Rovira, Monica Crane,Frederiksen Kristian Steen,Kevin Hanson, Jonathan Liss, Jeffrey Norton,Marc Suárez-Calvet,Craig Ritchie, Stephanie Rutrick,
    2025Neurology(2025)
    引用
    AI阅读
    加入学术空间
    5Real-world (RW) Analysis of Characteristics and Risk of Recurrence (ROR) in Black Patients (pts) with HR+/HER2− Early Breast Cancer (EBC) Eligible for NATALEE.
    Yara Abdou,Sonya A. Reid,Komal L. Jhaveri,Mark D. Pegram,Ilana Schlam,Joseph A. Sparano, Brooklyn T. Olumba, Elizabeth Chertow Santarsiero, Vaidyanathan Ganapathy,Murat Akdere, Fen Ye, Julia Kim,

    527 Background: The NATALEE trial showed statistically significant and clinically meaningful invasive disease–free survival benefit with ribociclib + nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in pts with stage II/III HR+/HER2− EBC at high ROR that deepened even after all pts were off ribociclib. Prior RW analyses have shown clinically meaningful ROR at 5 y despite endocrine therapy (ET) among NATALEE-eligible pts. TAILORx and RxPONDER reported racial disparities in recurrence and outcomes; however, further understanding of characteristics and unmet needs in Black pts is needed. This RW analysis describes pt characteristics and outcomes among Black pts eligible for NATALEE and receiving ET. Methods: Data from the US Flatiron Health EHR-derived deidentified database (2011-2023) were used. Selection criteria included pts aged ≥18 y with anatomical stage I-III (AJCC) HR+/HER2− EBC who had primary tumor surgical resection and started adjuvant ET. Pt characteristics and treatment patterns were analyzed in Black vs White pts eligible for NATALEE. ET (any) adherence was defined as proportion of days covered ≥80%. Recurrence-free survival (RFS), distant recurrence–free survival (DRFS), and overall survival (OS) were assessed descriptively and using multivariate Cox regression analysis. Results: A total of7481 pts met selection criteria. Overall, 41.2% (242/588) of Black and 33.0% (1697/5142) of White pts met NATALEE eligibility criteria. Compared with White pts, Black pts were younger (median age, 59 y vs 62 y) and more likely to be premenopausal (29.3% vs 23.8%), have anatomical stage III disease (35.1% vs 25.7%), more extensive nodal involvement (19.8% N0, 54.1% N1, 14.0% N2, and 7.0% N3 vs 24.0% N0, 53.3% N1, 11.3% N2, and 6.2% N3), higher use of Medicaid (13.2% vs 3.6%), lower socioeconomic status (lowest socioeconomic status quintile, 33.9% vs 11.4%), higher obesity (body mass index ≥30, 52.9% vs 38.4%), and lower ET adherence (3 y ET adherence: 57.0% vs 65.2%; 5 y ET adherence: 48.3% vs 56.2%). Five-y RFS, DRFS, and OS rates were 74.3%, 77.6%, and 85.0%, respectively, in Black pts and 83.2%, 84.5%, and 90.9% in White pts. Compared to White pts, Black pts had worse RFS (hazard ratio, 1.5; P =0.0045), DRFS (hazard ratio, 1.4; P =0.0272), and OS (hazard ratio, 1.7; P =0.0023) after adjusting for age, menopausal status, body mass index, tumor size and grade, nodal status, chemotherapy use, and socioeconomic status index. Conclusions: In a RW dataset of pts eligible for adjuvant ribociclib based on NATALEE inclusion criteria, Black pts had a higher recurrence risk and worse survival compared with White pts, underscoring the opportunity to improve outcomes and address racial disparities in Black pts with HR+/HER2− EBC.

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 45 篇论文

    合作机构(61)

    纪念斯隆凯特琳癌症中心合作论文 4
    小野薬品工業合作论文 3
    辉瑞合作论文 3
    丹娜—法伯癌症研究所合作论文 2
    Ipsen Inc.合作论文 2
    斯洛伐克共和国环境部合作论文 2
    安斯泰来制药合作论文 2
    西奈山伊坎医学院合作论文 2
    Baptist Medical Center合作论文 1
    Memorial Hermann合作论文 1

    机构统计